Shares of Dr. Reddy’s Laboratories Ltd today gained 1.1 per cent as the company has entered into a partnership with Hetero to distribute and market a drug used in the treatment of Hepatitis C in India.
“We expect the drug to be meaningful revenue driver for Dr. Reddy’s,’’ says Hitesh Mahida, research analyst, Antique Stock Broking Ltd.
He adds that the drug may enjoy operating margins of 25-30 per cent.